Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?

× No keyword cloud information.

6 in total

1. The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module.

Authors: Ke Chen; Kongming Wu; Xuanmao Jiao; Liping Wang; Xiaoming Ju; Min Wang; Gabriele Di Sante; Shaohua Xu; Qiong Wang; Kevin Li; Xin Sun; Congwen Xu; Zhiping Li; Mathew C Casimiro; Adam Ertel; Sankar Addya; Peter A McCue; Michael P Lisanti; Chenguang Wang; Richard J Davis; Graeme Mardon; Richard G Pestell
Journal: Cancer Res Date: 2015-03-13 Impact factor: 12.701

2. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.

Authors: Lei Li; Hongjun Xie; Liang Liang; Ye Gao; Dong Zhang; Leiya Fang; Soo Ok Lee; Jie Luo; Xingfa Chen; Xinyang Wang; Luke S Chang; Shuyuan Yeh; Yuzhuo Wang; Dalin He; Chawnshang Chang
Journal: Carcinogenesis Date: 2012-10-26 Impact factor: 4.944

3. Androgen receptor is a tumor suppressor and proliferator in prostate cancer.

Authors: Yuanjie Niu; Saleh Altuwaijri; Kuo-Pao Lai; Chun-Te Wu; William A Ricke; Edward M Messing; Jorge Yao; Shuyuan Yeh; Chawnshang Chang
Journal: Proc Natl Acad Sci U S A Date: 2008-08-22 Impact factor: 11.205

4. Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer.

Authors: Donge Tang; Jiaxi He; Yong Dai; Xinyan Geng; Qixin Leng; Haowu Jiang; Rui Sun; Songhui Xu
Journal: Cancer Gene Ther Date: 2021-04-14 Impact factor: 5.987

5. Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2α/androgen receptor signals.

Authors: Jie Luo; Soo Ok Lee; Yun Cui; Rachel Yang; Lei Li; Chawnshang Chang
Journal: Oncotarget Date: 2015-09-29

6. Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation.

Authors: Hua Xu; Yin Sun; Chi-Ping Huang; Bosen You; Dingwei Ye; Chawnshang Chang
Journal: Cancers (Basel) Date: 2020-03-30 Impact factor: 6.639

6 in total